MTST (MetaStat) Return-on-Tangible-Equity: 0.00% (As of Feb. 2018)


What is MetaStat Return-on-Tangible-Equity?

MetaStat MTST Return-on-Tangible-Equity is 0.00% as of Feb. 2018.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MetaStat's annualized net income for the quarter that ended in Feb. 2018 was $-3.89 Mil. MetaStat's average shareholder tangible equity for the quarter that ended in Feb. 2018 was $-1.16 Mil. Therefore, MetaStat's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2018 was N/A%.

The historical rank and industry rank for MetaStat's Return-on-Tangible-Equity or its related term are showing as below:

MTST's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.435
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

MetaStat  (OTCPK:MTST) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


MetaStat Return-on-Tangible-Equity Related Terms


MetaStat Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for MetaStat's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Return-on-Tangible-Equity Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity 0.00 0.00 0.00 0.00

MTST vs OBMP, NSPX, ATRX: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, MetaStat's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaStat Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where MetaStat's Return-on-Tangible-Equity falls into.



MetaStat Return-on-Tangible-Equity Calculation

MetaStat's annualized Return-on-Tangible-Equity for the fiscal year that ended in Feb. 2018 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Feb. 2018 )  (A: Feb. 2017 )(A: Feb. 2018 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Feb. 2018 )  (A: Feb. 2017 )(A: Feb. 2018 )
=-3.181/( (-2.795+-1.549 )/ 2 )
=-3.181/-2.172
=N/A %

MetaStat's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2018 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Feb. 2018 )  (Q: Nov. 2017 )(Q: Feb. 2018 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Feb. 2018 )  (Q: Nov. 2017 )(Q: Feb. 2018 )
=-3.888/( (-0.762+-1.549)/ 2 )
=-3.888/-1.1555
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2018) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
MetaStat (MTST) has a Return-on-Tangible-Equity of 0.00% as of Feb. 2018. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MetaStat and its competitors.
Is MetaStat's Return-on-Tangible-Equity too high?
MetaStat's current Return-on-Tangible-Equity is 0.00%.
How does MetaStat's Return-on-Tangible-Equity compare to OBMP and NSPX?
MetaStat's Return-on-Tangible-Equity of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MetaStat and its competitors. MetaStat's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MetaStat (MTST), the current Return-on-Tangible-Equity is 0.00% as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.